News for Phathom Pharmaceuticals, Inc. (PHAT)

Ӣ Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceutical

Phathom Pharmaceuticals (PHAT) to announce Q1 2025 financial results on May 1, 2025. Company to host live webcast at 8:00 am EDT with recording availabl

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. ( PHAT), a biopharmaceutical company focused on developing and commercial

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. ( PHAT), a biopharmaceutical company focused on developing and commercial

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on deve...

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Tuesday. Shares of IHS Holding Limited IHS rose sharply during Tuesday's session ...

Release Date: March 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Phathom Pharmac

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPHAT.OQ - Phathom Pharmaceuticals IncQ4 2024 Phathom Pharmaceuticals Inc Earnings CallMar 06,

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ETCompany ParticipantsEric Sciorilli - Head, Investor...

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 19.39% and 17.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

North Carolina-based Chimerix, Inc. (CMRX) is up over 69 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, I

Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related risk. Read more here.

Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior. Learn more on PHAT stock here.

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA ® (vonoprazan) Tablets

Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ETCompany ParticipantsEric Sciorilli - Head of...

Net Revenues: $16.4 million for Q3 2024, representing over 120% sequential quarter-over-quarter increase.Gross Profit: $14 million, with a gross margin of 86%,